- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02923531
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
November 30, 2022 updated by: X4 Pharmaceuticals
A Phase 1B/2A Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma
The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable.
Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiological response.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
New Jersey
-
Hackensack, New Jersey, United States
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of Renal Cell Carcinoma with a documented clear cell component (ccRCC).
- Currently receiving nivolumab and considered by Investigator to have the potential to derive clinical benefit from continuing treatment with nivolumab.
- Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria on current nivolumab treatment (prior to initiation of this study), has a best response of confirmed stable disease (SD) or confirmed progressive disease (PD). Confirmed SD or confirmed PD refers to a response that is confirmed by a second scan which is at least 4 weeks apart from the previous scan.
- At least one extra-renal measurable target lesion meeting the criteria of RECIST Version 1.1.
- Agree to use contraception from screening, through the study, and for at least 5 months after the last dose of nivolumab as follows: for women of childbearing potential agree to use highly-effective contraceptive methods; for males, agree to use a condom with sexual partner.
Exclusion Criteria:
- Pregnant or nursing.
- Life expectancy of less than 3 months.
- Performance status greater than or equal to (≥) 2 (Eastern Cooperative Oncology Group [ECOG] criteria).
- New York Heart Association (NYHA) Class III or IV, uncontrolled hypertension, or clinically significant arrhythmia.
- Previously received X4P-001.
- Has a second malignancy. Except: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type.
- Has active central nervous system (CNS) metastases (including evidence of cerebral edema by Magnetic Resonance Imaging [MRI], or progression from prior imaging study, or any requirement for steroids, or clinical symptoms of/from CNS metastases) within 28 days prior to study treatment. Subjects with known CNS metastases must have a baseline MRI scan within 28 days of study treatment.
- Ongoing clinical adverse events National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade greater than (>) 2 resulting from prior cancer therapies.
- Known history of Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS); or positive test for hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg).
- History of clinically significant or uncontrolled cardiac, hepatic, or pulmonary disease.
- Has had within the past 6 months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (NCI CTCAE Grade 3 or 4), chronic liver disease (meeting criteria for Child-Pugh Class B or C), or organ transplantation.
- Inadequate hematologic, hepatic, or renal function.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: X4P-001 Plus Nivolumab
Participants will receive X4P-001 400 milligrams (mg) (as 4 capsules of 100 mg each) orally once daily in combination with nivolumab 240 mg intravenous (IV) infusion (over 60 minutes) every 2 weeks.
Study medication will be administered in 28-day cycles and will continue until treatment-limiting toxicity or disease progression.
|
X4P-001 will be administered as per the dose and schedule specified in the arm.
Nivolumab will be administered as per the dose and schedule specified in the arm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame: From administration of first dose of study medication (Day 1) up to 30 days after last dose (up to 16 months)
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Drug-related TEAEs: TEAEs with possible, probable, definite, or missing relationship to study medication (X4P-001 or Nivolumab).
Serious AEs: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.
TEAEs were defined as events occurring on or after the first dose of study drug through 30 days after the last dose.
Any TEAEs included both serious and non-serious TEAEs.
A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in Reported AE section.
|
From administration of first dose of study medication (Day 1) up to 30 days after last dose (up to 16 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Concentration (Cmax) of X4P-001
Time Frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Samples were to be analyzed for X4P-001 concentration using reversed-phase high performance liquid chromatography (RP-HPLC) with tandem mass spectrometry (MS) detection.
|
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of X4P-001
Time Frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.
|
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Minimum Plasma Concentration (Cmin) of X4P-001
Time Frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.
|
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Time to Reach Cmax (Tmax) of X4P-001
Time Frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.
|
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1
|
Objective Response Rate (ORR): Percentage of Participants With Objective Response, Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Time Frame: From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)
|
ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR).
CR: Disappearance of all target and non-target lesions.
Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to less than (<) 10 millimeters (mm).
PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
|
From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)
|
Duration of Objective Response (DOR), Evaluated Using RECIST Version 1.1
Time Frame: Time from first CR or PR until the time of disease progression or death due to any cause (up to 15 months)
|
DOR was defined as the time from first CR or PR whichever comes first until the time of disease progression by RECIST v1.1 or death due to any cause.
CR: Disappearance of all target and non-target lesions.
Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to <10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm.
Unequivocal progression of existing non-target lesions.
The appearance of 1 or more new lesions was also considered progression.
|
Time from first CR or PR until the time of disease progression or death due to any cause (up to 15 months)
|
Time to Objective Response, Evaluated Using RECIST Version 1.1
Time Frame: From administration of first dose of study medication (Day 1) until first appearance of CR or PR (up to 15 months)
|
Time to objective response was defined as time from first administration of combination regimen to first CR or PR whichever comes first.
CR: Disappearance of all target and non-target lesions.
Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to <10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
|
From administration of first dose of study medication (Day 1) until first appearance of CR or PR (up to 15 months)
|
Disease Control Rate: Percentage of Participants With CR or PR or Stable Disease (SD), Evaluated Using RECIST Version 1.1
Time Frame: From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)
|
Disease control rate was defined as percentage of participants with best overall response of CR or PR or SD.
CR: Disappearance of all target and non-target lesions.
Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to <10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm.
Unequivocal progression of existing non-target lesions.
The appearance of 1 or more new lesions was also considered progression.
|
From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)
|
Progression Free Survival (PFS), Evaluated Using RECIST Version 1.1
Time Frame: From administration of first dose of study medication (Day 1) until disease progression or death from any cause (up to 15 months)
|
PFS was defined as the time from first administration of study medication until objective tumor progression or death from any cause.
Tumor progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm.
An unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.
|
From administration of first dose of study medication (Day 1) until disease progression or death from any cause (up to 15 months)
|
Time to Progression (TTP), Evaluated Using RECIST Version 1.1
Time Frame: From administration of first dose of study medication (Day 1) until disease progression (up to 15 months)
|
TTP was defined as the time from first administration of study medication until objective tumor progression.
Tumor progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm.
Unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.
|
From administration of first dose of study medication (Day 1) until disease progression (up to 15 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Chief Medical Officer, X4 Pharmaceuticals, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 7, 2016
Primary Completion (Actual)
August 8, 2018
Study Completion (Actual)
August 8, 2018
Study Registration Dates
First Submitted
September 30, 2016
First Submitted That Met QC Criteria
September 30, 2016
First Posted (Estimate)
October 4, 2016
Study Record Updates
Last Update Posted (Estimate)
December 29, 2022
Last Update Submitted That Met QC Criteria
November 30, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- X4P-001-RCCB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clear Cell Renal Cell Carcinoma
-
Celldex TherapeuticsTerminatedKidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Guru SonpavdePfizer; Hoosier Cancer Research NetworkWithdrawnKidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney CarcinomaUnited States
-
Peloton Therapeutics, Inc.Active, not recruitingA Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Kidney Cancer | Clear Cell Renal Cell Carcinoma | Glioblastoma | Solid Tumor | Glioblastoma Multiforme | Advanced Solid Tumors | GBM | Solid Tumor, Adult | Solid Carcinoma | Glioblastoma, Adult | ccRCC | RCC, Clear Cell Adenocarcinoma | RCC | Renal Cell Carcinoma, Metastatic | Renal Cell Carcinoma Recurrent | Renal Cell...
-
Queen Mary University of LondonAstraZeneca; Vall d'Hebron Institute of OncologyActive, not recruitingRenal Clear Cell Carcinoma | Renal Papillary Cell CarcinomaUnited Kingdom
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
-
University of WashingtonMerck Sharp & Dohme LLC; Prometheus LaboratoriesTerminatedMetastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell CancerUnited States
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell CarcinomaChina
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
Clinical Trials on X4P-001
-
X4 PharmaceuticalsCovanceTerminatedHealthyUnited States
-
X4 PharmaceuticalsCompletedWaldenstrom's MacroglobulinemiaUnited States, Greece
-
X4 PharmaceuticalsActive, not recruiting
-
X4 PharmaceuticalsNot yet recruiting
-
X4 PharmaceuticalsCompleted
-
Abbisko Therapeutics Co, LtdEnrolling by invitationTriple Negative Breast CancerChina
-
X4 PharmaceuticalsActive, not recruitingWHIM SyndromeUnited States, Denmark, Australia, Austria, France, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Russian Federation, Spain, Turkey
-
X4 PharmaceuticalsCompleted
-
X4 PharmaceuticalsCompletedClear Cell Renal Cell CarcinomaUnited States, Korea, Republic of
-
Toll Biotech Co. Ltd. (Beijing)Recruiting